EGFR and non-small cell lung carcinoma: Following our previous research on the L858R-mutated subgroup [44], we conducted a network meta-analysis (NMA) to evaluate the efficacy of all first-line treatments in Asian patients with advanced EGFR-mutated NSCLC harboring 19del.